ILUMYA® (tildrakizumab) Pen (Auto-Injector) Now Available for Canadians Living with Moderate-to-Severe Plaque Psoriasis

Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased to ...
Monthly Prescribing Reference

Ilumya Now Available for the Treatment of Plaque Psoriasis

Analyses presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2018 meeting, showed that compared with non-targeted treatments like apremilast, Ilumya was found to be the most cost-effective.
MarketWatch

ILUMYA(R) (tildrakizumab-asmn) Found Effective for Treatment of Moderate-to-Severe Plaque Psoriasis Affecting Nails in Study Presented at 2025 AAD Conference

Data Presented at American Academy of Dermatology Shows Significant Improvement in Moderate-to-Severe Nail Psoriasis with No New Safety Signals PRINCETON, N.J., March 7, 2025 /PRNewswire/ -- Sun ...
Business Insider

Sun Pharma Announces U.S. FDA Approval of ILUMYA™ (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis

MUMBAI, India and PRINCETON, N.J., March 21, 2018 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 ...
Business Insider

ILUMYA™ (tildrakizumab-asmn) 3-Year Data Demonstrates Sustained Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis

MUMBAI, India and PRINCETON, N.J., March 1, 2019 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 ...
Seeking Alpha

Will Ilumya Kill Valeant's Psoriasis Dreams?

Sun Pharma's Ilumya received FDA approval to treat moderate-to-severe plaque psoriasis. If it markets Ilumya on par with VRX's Siliq it could compensate for its late entrance to the psoriasis market.
Nasdaq

-First Trial of ILUMYA(TM) in Patients with Psoriatic Arthritis Met Primary Efficacy Endpoint, with No Evident Safety Concerns

MUMBAI, India and PRINCETON, N.J., June 14, 2019 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 ...
Healio

4-year data demonstrate safety, efficacy of Ilumya in plaque psoriasis

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Healio

FDA approves Ilumya for moderate-to-severe plaque psoriasis

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Today, Sun Pharma announced that Ilumya ...